Navigation Links
Cardiac Science to Present at the Roth 21st Annual OC Growth Stock Conference
Date:2/17/2009

sor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's expectations regarding revenues for the fourth quarter and full year 2008, charges relating to the restructuring announced in this press release, and expectations regarding the impact of the restructuring on 2009 operating results. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in Cardiac Science Corporation's Annual Report on Form 10-K for the year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2008. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

    For more information,
    Company Contact:                Investor Contact:    Media Contact:
    Mike Matysik                    Doug Sherk           Christopher Gale
    Cardiac Science Corporation     Jenifer Kirtland     EVC Group Inc.
   
'/>"/>
SOURCE Cardiac Science
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sudden Cardiac Death Rare in Young Athletes
2. Global Economic Meltdown - Is the European Cardiac Rhythm Management Market Spared?
3. TV News Coverage Reports on InnerCools CoolBlue System Treatment of Cardiac Shock Patient Following Childbirth at Rush Hospital, Chicago
4. Worlds First Cardiac Adult Stem Cell Trial to Take Place in Louisville
5. iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies
6. Cardiac Science Increases R&D Capacity With 3-year Syncroness Agreement
7. The Sudden Cardiac Arrest Association Shoots Straight for the Heart
8. Experts Urge Limits on Use of Cardiac CT Scans
9. Proton pump inhibitors increase risk of heart attacks for patients on common cardiac drug
10. Easing regulations does not mean lower quality of cardiac care
11. New stretchable electrodes created to study stresses on cardiac cells
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:PRA International Hosts an Infectious Diseases Audio Conference 2PRA International Hosts an Infectious Diseases Audio Conference 3Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 49191 1Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 49191 2Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 49191 3Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 49187 1Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 49187 2Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 49187 3Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 1Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 2Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 3Arena Pharmaceuticals to Receive 24100 Million from Deerfield Management 49183 4